BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34287250)

  • 1. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
    Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
    Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
    Lambert LK; Balneaves LG; Howard AF; Chia SLK; Gotay CC
    Curr Oncol; 2021 Apr; 28(2):1472-1482. PubMed ID: 33918560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
    Clancy C; Lynch J; OConnor P; Dowling M
    Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
    En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
    Samuel CA; Turner K; Donovan HAS; Beckjord E; Cardy A; Dew MA; van Londen GJ
    Support Care Cancer; 2017 Dec; 25(12):3723-3731. PubMed ID: 28681126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.
    Green SMC; French DP; Graham CD; Hall LH; Rousseau N; Foy R; Clark J; Parbutt C; Raine E; Gardner B; Velikova G; Moore SJL; Buxton J; ; Smith SG
    BMC Health Serv Res; 2022 Aug; 22(1):1081. PubMed ID: 36002831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
    Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
    Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
    Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
    Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
    Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
    Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence.
    Brett J; Boulton M; Fenlon D; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery BA; Morgan A; Morris C; Watson EK
    Patient Prefer Adherence; 2018; 12():291-300. PubMed ID: 29497284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Telushi E; Lapitan E; Nightingale G; Miller S; Wen KY
    Res Sq; 2023 Jan; ():. PubMed ID: 36778385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.